GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (FRA:TAL) » Definitions » Capex-to-Operating-Income

Taro Pharmaceutical Industries (FRA:TAL) Capex-to-Operating-Income : 2.17 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Taro Pharmaceutical Industries Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Taro Pharmaceutical Industries's Capital Expenditure for the three months ended in Dec. 2023 was €-31.62 Mil. Its Operating Income for the three months ended in Dec. 2023 was €14.57 Mil.

Hence, Taro Pharmaceutical Industries's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 2.17.


Taro Pharmaceutical Industries Capex-to-Operating-Income Historical Data

The historical data trend for Taro Pharmaceutical Industries's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Capex-to-Operating-Income Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.12 0.12 0.89 1.12

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 0.92 - 1.48 2.17

Competitive Comparison of Taro Pharmaceutical Industries's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Capex-to-Operating-Income falls into.



Taro Pharmaceutical Industries Capex-to-Operating-Income Calculation

Taro Pharmaceutical Industries's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-18.537) / 16.545
=1.12

Taro Pharmaceutical Industries's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-31.616) / 14.565
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taro Pharmaceutical Industries  (FRA:TAL) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Taro Pharmaceutical Industries Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (FRA:TAL) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Taro Pharmaceutical Industries (FRA:TAL) Headlines

From GuruFocus

TAL Education Group Files Its Annual Report on Form 20-F

By PRNewswire PRNewswire 05-31-2023